ImmunityBio Announces NCCN Guidelines Update for ANKTIVA in NMIBC Treatment

ImmunityBio (IBRX) has announced that the NCCN Clinical Practice Guidelines have been updated to include ANKTIVA for the treatment of papillary-only non-muscle invasive bladder cancer (NMIBC).